[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised to treatment with Tesofensine 0.25, 0.5, or 1.0 mg, or placebo daily for 24 weeks. Treatment with Tesofensine resulted in a mean weight reduction of 4.5, 9.2 and 10.6% higher than that of placebo for 0.25, 0.5 and 1.0 mg, respectively. Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of safety and efficacy of 0.5 mg Tesofensine need confirmation in phase III trials.
Nielsen
Anne-Louise Hother
AL
Institut for Human Ernaering, Det Biovidenskabelige Fakultet, Københavns Universitet, DK-1958 Frederiksberg C. alhn@life.ku.dk
Larsen
Thomas Meinert
TM
Madsbad
Sten
S
Breum
Leif
L
Jensen
Thomas Jon
TJ
Kroustrup
Jens Peter
JP
Astrup
Arne
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
D019440:Anti-Obesity Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; C518479:Tesofensine